Trial Profile

Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Interferon alpha-2a
Indications Renal cell carcinoma
Focus Registrational; Therapeutic Use
Acronyms INTORACT
Sponsors Pfizer; Wyeth

Most Recent Events

22 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
08 Jun 2015 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported ClinicalTrials.gov record.
11 Dec 2014 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com